Zeo ScientifiX Revenue Climbs 33% to $1.45M as Q1 Net Loss Narrows

Zeo ScientifiX, Inc., a Nevada-based scientific instrumentation company, reported revenue of $1.45 million for the three months ending January 31, 2026, a 33% increase from $1.09 million in the same quarter of fiscal 2025. The company posted a net loss of $852,000 for the quarter, narrowing from a loss of $1.24 million a year earlier. Read more earnings reports.

Gross profit rose to $1.17 million from $899,000 in the prior-year quarter, reflecting a gross margin of approximately 81% compared to 82% a year earlier. Cost of goods sold increased to $281,000 from $191,000.

Operating loss improved to $878,000 from $1.25 million in the year-ago period. The improvement came despite higher operating expenses, as the company's revenue growth outpaced cost increases. Labor and related expenses totaled $161,000 for the quarter, compared to a credit of $4,000 in the prior-year period. Research and development expenses rose to $19,000 from $6,000.

Cash flow from operations was negative $471,000 for the three months ending January 31, 2026, compared to positive cash flow of $65,000 in the same period a year earlier. The company reported cash and restricted cash of $1.03 million as of January 31, 2026, up from $221,000 as of October 31, 2025.

The balance sheet showed total assets of $2.57 million as of the quarter end, up 68% from $1.53 million three months earlier. Current assets more than doubled to $2.01 million from $958,000. Inventory increased to $502,000 from $423,000, and accounts receivable rose to $63,000 from $35,000.

Total liabilities remained essentially flat at $2.95 million as of January 31, 2026, compared to $2.95 million as of October 31, 2025. The company reported a stockholders' deficit of $383,000 as of the quarter end, an improvement from a deficit of $1.42 million three months earlier and $1.81 million a year earlier.

Cash from financing activities totaled $1.29 million for the quarter, compared to an outflow of $2,000 in the prior-year period. The company ended the quarter with 7.61 million common shares outstanding, up from 6.75 million shares at the end of the prior quarter.

The company reported a basic and diluted loss per share of $0.12 for the three months ending January 31, 2026, compared to a loss per share of $0.20 in the same quarter of fiscal 2025, based on weighted average shares outstanding of 7.02 million and 6.34 million, respectively.